Susanne Markmann

521 total citations
23 papers, 305 citations indexed

About

Susanne Markmann is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Susanne Markmann has authored 23 papers receiving a total of 305 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Cancer Research, 10 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Susanne Markmann's work include Breast Cancer Treatment Studies (10 papers), Ovarian cancer diagnosis and treatment (9 papers) and Advanced Breast Cancer Therapies (5 papers). Susanne Markmann is often cited by papers focused on Breast Cancer Treatment Studies (10 papers), Ovarian cancer diagnosis and treatment (9 papers) and Advanced Breast Cancer Therapies (5 papers). Susanne Markmann collaborates with scholars based in Germany, United States and Switzerland. Susanne Markmann's co-authors include J. Hilfrich, Sherko Kümmel, Mahdi Rezai, Andreas Schneeweiß, Kay Friedrichs, Holger Eidtmann, Thorsten Kühn, Holm Eggemann, Jens‐Uwe Blohmer and W. Eiermann and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Susanne Markmann

23 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Susanne Markmann Germany 8 138 123 120 63 59 23 305
Sushmita Gordhandas United States 9 74 0.5× 125 1.0× 95 0.8× 82 1.3× 82 1.4× 35 344
M Warm Germany 7 123 0.9× 47 0.4× 106 0.9× 30 0.5× 23 0.4× 23 239
Robyn Sayer United States 10 87 0.6× 199 1.6× 79 0.7× 32 0.5× 73 1.2× 17 404
Ying‐Yang Liao China 11 141 1.0× 47 0.4× 99 0.8× 21 0.3× 47 0.8× 15 308
Shujie Pang China 8 60 0.4× 114 0.9× 52 0.4× 25 0.4× 64 1.1× 22 282
Aude-Marie Savoye France 7 47 0.3× 82 0.7× 159 1.3× 26 0.4× 40 0.7× 19 312
Emily Prendergast United States 10 89 0.6× 109 0.9× 78 0.7× 37 0.6× 75 1.3× 29 326
Steve Skates United States 6 37 0.3× 184 1.5× 41 0.3× 33 0.5× 80 1.4× 7 293
Elke Burger Germany 8 122 0.9× 68 0.6× 165 1.4× 18 0.3× 104 1.8× 12 318
Maria M. Rubinstein United States 10 50 0.4× 107 0.9× 105 0.9× 28 0.4× 124 2.1× 26 304

Countries citing papers authored by Susanne Markmann

Since Specialization
Citations

This map shows the geographic impact of Susanne Markmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanne Markmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanne Markmann more than expected).

Fields of papers citing papers by Susanne Markmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanne Markmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanne Markmann. The network helps show where Susanne Markmann may publish in the future.

Co-authorship network of co-authors of Susanne Markmann

This figure shows the co-authorship network connecting the top 25 collaborators of Susanne Markmann. A scholar is included among the top collaborators of Susanne Markmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanne Markmann. Susanne Markmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nabieva, Naiba, Antje Belau, Steffi Busch, et al.. (2023). The Endocrine Treatment Landscape for Patients with HR+ HER2− Early-stage Breast Cancer in Germany Before the Introduction of CDK4/6 Inhibitor Therapy – A Real-World Analysis. Geburtshilfe und Frauenheilkunde. 83(9). 1127–1137. 2 indexed citations
2.
Sehouli, Jalid, Felix Hilpert, Sven� Mahner, et al.. (2016). Topotecan (T) ± sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO–AGO intergroup Trial—TRIAS.. Journal of Clinical Oncology. 34(15_suppl). 5522–5522. 2 indexed citations
3.
Mustea, Alexander, Dominique Koensgen, Antje Belau, et al.. (2013). Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology). Cancer Chemotherapy and Pharmacology. 72(5). 975–983. 13 indexed citations
4.
Patejdl, Robert, Susanne Markmann, R. Benecke, & Matthias Wittstock. (2013). Severe acute motor neuropathy after treatment with triple tyrosine kinase inhibitor BIBF 1120 (Nintedanib). Clinical Neurology and Neurosurgery. 115(9). 1851–1852. 5 indexed citations
5.
6.
7.
Mahner, Sven�, Gülten Oskay-Özcelik, Stefan Fuxius, et al.. (2012). A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. Journal of Cancer Research and Clinical Oncology. 138(8). 1413–1419. 14 indexed citations
8.
9.
10.
Gluz, Oleg, C Liedtke, Susanne Markmann, et al.. (2010). WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.. Journal of Clinical Oncology. 28(15_suppl). TPS106–TPS106. 2 indexed citations
11.
12.
Leunig, Alexander, Frieder Braunschweig, Miriam Havel, et al.. (2009). [Chronic rhinosinusitis and aspirin intolerance].. PubMed. 151(5). 44–5. 1 indexed citations
13.
Stengel, Dirk, Philipp Harter, Christian Kurzeder, et al.. (2009). Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO). Journal of Clinical Oncology. 27(15_suppl). 5553–5553. 1 indexed citations
14.
Reimer, Toralf, Rainer Fietkau, Susanne Markmann, Angrit Stachs, & Bernd Gerber. (2007). How Important is the Axillary Nodal Status for Adjuvant Treatment Decisions at a Breast Cancer Multidisciplinary Tumor Board? A Survival Analysis. Annals of Surgical Oncology. 15(2). 472–477. 7 indexed citations
15.
Stengel, Dirk, Andreas du Bois, Susanne Markmann, et al.. (2007). Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). Journal of Clinical Oncology. 25(18_suppl). 5526–5526. 6 indexed citations
16.
Markmann, Susanne, Bernd Gerber, & Volker Briese. (2007). Prognostic value of Ca 125 levels during primary therapy.. PubMed. 27(4A). 1837–9. 12 indexed citations
17.
Reimer, Toralf, Rainer Fietkau, Susanne Markmann, Angrit Stachs, & B. Gerber. (2007). How important is the axillary nodal status for adjuvant treatment decisions at a breast cancer multidisciplinary tumor board? A survival analysis. Journal of Clinical Oncology. 25(18_suppl). 11041–11041. 1 indexed citations
18.
Rohr, Uwe D., C. Oberhoff, Susanne Markmann, et al.. (2005). The safety of synthetic paclitaxel by intralesional delivery with OncoGel™ into skin breast cancer metastases: method and results of a clinical pilot trial. Archives of Gynecology and Obstetrics. 2 indexed citations
19.
Mylonas, Ioannis, et al.. (2003). Unilateral ovarian agenesis: report of three cases and review of the literature. Archives of Gynecology and Obstetrics. 268(1). 57–60. 24 indexed citations
20.
Gerber, Bernd, Annette Krause, Susanne Markmann, et al.. (2001). Effectiveness of Trastuzumab (Herceptin<sup>TM</sup>) in a Patient with Locally Recurrent Breast Cancer after Cardiac Failure Caused by Severe Cytotoxic Pretreatment. Oncology. 61(4). 271–274. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sushmita Gordhandas Breakdown of academic impact, for papers by M Warm Breakdown of academic impact, for papers by Robyn Sayer Breakdown of academic impact, for papers by Ying‐Yang Liao Breakdown of academic impact, for papers by Shujie Pang Breakdown of academic impact, for papers by Aude-Marie Savoye Breakdown of academic impact, for papers by Emily Prendergast Breakdown of academic impact, for papers by Steve Skates Breakdown of academic impact, for papers by Elke Burger Breakdown of academic impact, for papers by Maria M. Rubinstein
Rankless by CCL
2026